Clasp Therapeutics

Clasp Therapeutics is a clinical-stage immuno-oncology company building off-the-shelf, antibody-like T cell engagers that target cancer driver mutations presented on tumor cells via HLA. Spun out of Johns Hopkins and co-founded by cancer-genetics pioneer Bert Vogelstein and immunotherapy leader Drew Pardoll, Clasp uses its proprietary pHLAre platform to redirect a patient's own T cells to kill tumors with what the company calls absolute specificity - hitting mutant peptides found only on cancer cells while sparing healthy tissue. The company launched publicly in March 2024 with a $150 million Series A and dosed its first patient in April 2025.